A rapid CRISPR-based nanodroplet assay enables direct clinical identification of mycobacteria species.

A CRISPR-based nanodroplet assay accurately identifies 15 mycobacterial species within 3.5 hours, surpassing traditional culture methods in speed and precision.

• Why it matters: Rapid and accurate diagnosis of nontuberculous mycobacterial infections is critical due to their rising incidence and the limitations of current culture-based identification, which is slow and often inaccurate.
• What they did: The team developed CANDI, a multiplexed diagnostic platform that combines species-agnostic amplification with species-specific CRISPR-Cas12a detection in fluorescence-barcoded nanodroplets, enabling simultaneous analysis of multiple targets.
• The result: CANDI achieved 97.08% sensitivity and 99.7% specificity in clinical samples, providing rapid, subspecies-level results and offering a scalable, precise alternative to culture-based diagnostics for complex Mycobacterium infections.